TITLE

Metabolic Bone Disease

AUTHOR(S)
Frame, Boy; Parfitt, A. M.
PUB. DATE
October 1972
SOURCE
Annals of Internal Medicine;Oct72, Vol. 77 Issue 4, p655
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on methods and techniques for diagnosing several metabolic bone diseases, as discussed during the 1972 Clinical Aspects of Metabolic Bone Disease symposium in Detroit, Michigan. Information on the photon absorption method; Details on the use of calcitonin, mithramycin and diphosphonates in the treatment of Paget's disease; Discussion on osteoporoses and renal osteodystrophy.
ACCESSION #
6944124

 

Related Articles

  • CORRELATIONS WITH BONE MINEAL DENSITY IN MALE PATIENTS WITH CHRONIC ALCOHOLIC LIVER DISEASE. Barbour, J.; Kelly, C. // Gut;Apr2003 Supplement 1, Vol. 52, pA102 

    Background: Men with alcohol dependence and related liver dysfunction have multiple risk factors for metabolic bone disease. In a case controlled study we studied the prevalence of osteoporosis and we identified surrogate markers of Iow bone mass and risk factors for osteoporosis in these...

  • Bifosfonat Tedavisinin Hareketli Bölümlü Protez Kullanan Hastalar Ãœzerine Etkisi. ŞAHİN, Meryem; ÜNALAN, Fatma; ÇAKARER, Sırmahan // Turkiye Klinikleri. Dishekimligi Bilimleri Dergisi;2019, Vol. 25 Issue 2, p220 

    Bisphosphonates; is very effective in preventing bone resorption in the treatment of metabolic bone diseases such as osteoporosis, multiple myeloma, hypercalcemia, Paget's disease, fibrous dysplasia. However, it causes some complications by suppressing restructuring in the bones. The most...

  • mTORC1 Activation in Osteoclasts Prevents Bone Loss in a Mouse Model of Osteoporosis. Hiraiwa, Manami; Ozaki, Kakeru; Yamada, Takanori; Iezaki, Takashi; Park, Gyujin; Fukasawa, Kazuya; Horie, Tetsuhiro; Kamada, Hikari; Tokumura, Kazuya; Motono, Mei; Kaneda, Katsuyuki; Hinoi, Eiichi // Frontiers in Pharmacology;6/13/2019, pN.PAG 

    The mechanistic/mammalian target of rapamycin (mTOR) is widely implicated in the pathogenesis of various diseases, including cancer, obesity, and cardiovascular disease. Bone homeostasis is maintained by the actions of bone-resorbing osteoclasts and bone-forming osteoblasts. An imbalance in the...

  • No Alteration in Bone Mineral Density in Patients with Periodontitis. Hattatoglu-Sönmez, E.; Özçakar, L.; Gökçe-Kutsal, Y.; Karaağaoğlu, E.; Demiralp, B.; Nazliel-Erverdi, H. // Journal of Dental Research;Jan2008, Vol. 87 Issue 1, p79 

    Alveolar bone destruction can be magnified in the presence of generalized skeletal disorders. We questioned whether severe generalized periodontitis patients display signs of bone metabolism disturbances. Our objective was to assess skeletal bone mineral density (BMD) and biochemical bone...

  • Altered calcitonin gene in a young patient with osteoporosis. Alevizaki, M.; Stevenson, J.C.; Girgis, S.I.; MacIntyre, I.; Legon, S. // BMJ: British Medical Journal (International Edition);5/6/89, Vol. 298 Issue 6682, p1215 

    Assessment of altered calcitonin in a young patient with osteoporosis. Analysis of genomic clones representing the calcitonin gene; Identification of a single base insertion in the intron separating exons IV and V of the gene; Importance of calcitonin in the prevention of bone loss.

  • Osteoporosis and calcitonin deficiency. Stevenson, John C.; White, Michael C.; Joplin, Graham F.; MacIntyre, Iain // British Medical Journal (Clinical Research Edition);10/9/1982, Vol. 285 Issue 6347, p1010 

    Examines the association between osteoporosis and calcitonin deficiency. Signs and symptoms of the disease; Treatment and management of the disease process; Development of osteoporosis after puberty.

  • Efficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis. Reginster, Y.; Reginster, J-Y. // BioDrugs;1998, Vol. 10 Issue 4, p295 

    Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic bone diseases characterised by excessive bone resorption, such as osteoporosis. Most...

  • Oral calcitonin tablets safe, effective in ORACAL trial.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p31 

    The article reports that the ORACAL trial has revealed that postmenopausal women with osteoporosis who received oral recombinant salmon calcitonin experienced improvements in lumbar spine bone mineral density at 48 weeks.

  • Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Overgaard, Kirsten; Hansen, Marc Allan; Jensen, Signe Birk; Christiansen, Claus // BMJ: British Medical Journal (International Edition);9/5/92, Vol. 305 Issue 6853, p556 

    Examines the effects of salmon calcitonin given intranasally on bone mass and bone turnover. Reduction of fracture rates in elderly women with osteoporosis; Description of osteoporosis; Measurement of the bone mineral content of th distal forearm.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics